nach oben

Erschienen in:

22.02.2019 | Typ-1-Diabetes | DDG Praxisempfehlungen

Therapie des Typ-1-Diabetes

Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057–013; 2. Auflage), Stand: 30. Juni 2018

verfasst von: Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel, Diana Droßel

Erschienen in: Die Diabetologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://www.deutsche-diabetes-gesellschaft.de/ueber-uns.html) befinden sich unter „Leitlinien → Praxisempfehlungen“ alle PDFs zum kostenlosen Download. …

American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2017; 40 (Suppl. 1): S11–S24. https://doi.org/10.2337/dc17-S005. EK IVCrossRef

Johnson DD, Palumbo PJ, Chu CP. Diabetic ketoacidosis in a communitybased population. Mayo Clin Proc 1980; 55 (2): 83–88. EK III

Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2 (7892): 1279–1283. EK IIICrossRef

Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulindependent diabetics before insulin treatment. Science 1983; 222 (4630): 1337–1339. EK IIICrossRef

Wiest-Ladenburger U, Hartmann R, Hartmann U et al. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 1997;46 (4): 565–571. EK III

Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52 (5):1128–1136. EK III

Törn C, Mueller PW, Schlosser M et al. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51 (5): 846–852. EK III

Schlosser M, Mueller PW, Torn C et al. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010; 53 (12): 2611–2620. EK III

Imagawa A, Hanafusa T, Miyagawa J et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000;342 (5): 301–307. EK IIICrossRef

10.

National Institute for Health and Clinical Excellence. Type 1 diabetes in adults: diagnosis and management. 2015. EK IV

11.

American Diabetes Association. Standards of Medical Care in Diabetes—2017. Diabetes Care 2017; 40 (Suppl. 1). EK IV

12.

DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329 (14): 977–986. EK Ib

13.

Fanelli CG, Epifano L, Rambotti AM et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42 (11): 1683–1689. EK IIb

14.

Fritsche A, Stefan N, Haring H et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134 (9): 729–736. EK IIb

15.

Deutsche Diabetes Gesellschaft. S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Angemeldete Leitlinie in Entstehung. Im Internet: http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/057-017.html. EK IV

16.

Lipska KJ, Hirsch IB, Riddle MC. Human Insulin for Type 2 Diabetes: An Effective, Less-Expensive Option. JAMA 2017; 318 (1): 23–24. https://doi.org/10.1001/jama.2017.6939. EK IV/LoE 4CrossRefPubMed

17.

Lucidi P, Porcellati F, Marinelli Andreoli A et al. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. Diabetes Care 2015; 38 (12): 2204–2210. https://doi.org/10.2337/dc15-0801. EK IVCrossRef

18.

Wutte A, Plank J, Sinner F. Dose-response relationship and within-subject variability of insulin detemir and NPH insulin in subjects with Type 1 diabetes. Diabetes 2004; 53 (Suppl. 2): A152. EK IV

19.

Becker RHA, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47 (1): 7–20. https://doi.org/10.2165/00003088-200847010-00002. EK IIICrossRefPubMed

20.

Weyer C, Heise T, Heinemann L. Insulin Aspart in a 30/70 Premixed Formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20 (10): 1612–1614. https://doi.org/10.2337/diacare.20.10.1612. EK IIICrossRefPubMed

21.

Woodworth JR, Howey DC, Bowsher RR et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 1994; 17 (5): 366–371. EK II

22.

Heise T, Hövelmann U, Nosek L et al (2015) Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. Ek Iii 11(8):1193–1201. https://doi.org/10.1517/17425255.2015.1058779 CrossRef

23.

Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53 (9):787–800. https://doi.org/10.1007/s40262-014-0165-y. EK ICrossRefPubMedPubMedCentral

24.

Nosek L, Coester HV, Roepstorff C et al (2014) Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. Clin Drug Investig. Ek Ii 34(9):673–679. https://doi.org/10.1007/s40261-014-0218-x CrossRef

25.

Koehler G, Treiber G, Wutte A et al. Pharmacodynamics of the longacting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab 2014; 16 (1): 57–62. https://doi.org/10.1111/dom.12178. EK IICrossRef

26.

Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9 (5): 648–659. https://doi.org/10.1111/j.1463-1326.2007.00756.x. EK ICrossRef

27.

Becker RHA, Dahmen R, Bergmann K et al. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units ·mL-1: The ELEMENT 1 study. Diabetes Care 2015; 38 (4): 637–643. https://doi.org/10.2337/dc14-0006. EK IICrossRef

28.

Shiramoto M, Eto T, Irie S et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015; 17 (3): 254–260. https://doi.org/10.1111/dom.12415. EK IICrossRefPubMed

29.

Heise T, Pieber TR, Danne T et al. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clin Pharmacokinet 2017; 56 (5): 551–559. https://doi.org/10.1007/s40262-017-0514-8. EK IICrossRef

30.

Heise T, Eckers U, Kanc K et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: A randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008; 10 (6): 479–485. https://doi.org/10.1089/dia.2008.0019. EK IICrossRef

31.

Famulla S, Hovelmann U, Fischer A et al. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care 2016; 39 (9): 1486–1492. https://doi.org/10.2337/dc16-0610. EK II/LoECrossRef

32.

Heise T, Weyer C, Serwas A et al. Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin. Diabetes Care 1998; 21 (5): 800–803. https://doi.org/10.2337/diacare.21.5.800. EK IIICrossRefPubMed

33.

Rave K, Heinemann L, Puhl L et al. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Diabetes Care 1999; 22 (5): 865–866. EK III

34.

Brunner M, Pieber T, Korsatko S et al. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes. Drugs Aging 2015; 32 (7): 583–590. https://doi.org/10.1007/s40266-015-0272-y. EK IICrossRef

35.

Heise T, Nosek L, Roepstorff C et al. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Ther 2014; 5 (1): 255–265. https://doi.org/10.1007/s13300-014-0070-2. EK IICrossRef

36.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-02. Version 1.0; 2007.. EK Ia

37.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-01. Version 1.0; 2010.. EK Ia

38.

Singh SR, Ahmad F, Lal A et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180 (4): 385–397. EK Ia

39.

Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11 (4): 372–378. EK Ia

40.

Mullins P, Sharplin P, Yki-Jarvinen H et al. Negative binomial metaregression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29 (8): 1607–1619. EK Ia

41.

Ashwell SG, Bradley C, Stephens JW et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31 (6): 1112–1117. EK Ib

42.

Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47 (4): 622–629. EK IbCrossRef

43.

Bühn S, Breuing J, Mathes T et al. Evidenzbericht zu ausgewählten Rechercheaufträgen im Rahmen der S3-Leitlinie „Therapie des Typ-1-Diabetes“. Witten/Herdecke: IFOM – Institut für Forschung in der Operativen Medizin (Universität Witten/Herdecke). 2016

44.

Fullerton B, Siebenhofer A, Jeitler K et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev 2016; (6): CD012161. https://doi.org/10.1002/14651858.CD012161. EK Ia/LoE 1++CrossRef

45.

Vardi M, Jacobson E, Nini A et al. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev 2008; (3): CD006297. EK Ia/LoE 1+

46.

Retnakaran R, Hochman J, DeVries JH et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27 (11): 2590–2596. EK Ia

47.

Fatourechi MM, Kudva YC, Murad MH et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009; 94 (3):729–740. EK IaCrossRef

48.

Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51 (6): 941–951. EK Ia

49.

Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25 (7): 765–774. EK IIb

50.

Bolli GB, Kerr D, Thomas R et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009; 32 (7): 1170–1176. EK IbCrossRef

51.

Steineck I, Cederholm J, Eliasson B et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18168 people with type 1 diabetes: observational study. BMJ 2015; 350: h3234. EK IIbCrossRef

52.

Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med 2007; 24 (6): 607–617. EK Ia

53.

Hoogma RP, Hammond PJ, Gomis R et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‑nations trial. Diabet Med 2006; 23 (2): 141–147. EK Ib

54.

Mukhopadhyay A, Farrell T, Fraser RB et al. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197 (5): 447–456. EK IaCrossRef

55.

Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007; 3: CD005542. EK Ia

56.

Chen R, Ben-Haroush A, Weismann-Brenner A et al. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 2007; 197 (4): 404–405. EK IIbCrossRef

57.

Cypryk K, Kosinski M, Kaminska P et al. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. Pol Arch Med Wewn 2008; 118 (6): 339–344. EK IIb

58.

Gimenez M, Conget I, Nicolau J et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol 2007; 44 (1): 34–37. EK IIICrossRef

59.

Alto WA, Meyer D, Schneid J et al. Assuring the accuracy of home glucose monitoring. J Am Board Fam Pract 2002; 15 (1): 1–6. EK III

60.

Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006; 295 (14): 1688–1697. EK IVCrossRef

61.

Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Diabetes – Strukturierte Schulungsprogramme – Langfassung, 1. Auflage. Version 4. Im Internet: http://www.dm-schulung.versorgungsleitlinien.de; Stand: 4. Nov. 2017. EK IV

62.

Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes (Teil 1). Diabetologie und Stoffwechsel 2013; a 8 (3): 198–242. https://doi.org/10.1055/s-0033-1335785. EK IVCrossRef

63.

Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes (Teil 2). Diabetologie und Stoffwechsel 2013; b 8 (4): 292–324. https://doi.org/10.1055/s-0033-1335889. EK IVCrossRef

64.

Hermanns N, Kulzer B, Krichbaum M. Problemspezifische Patientenschulung. Übersicht zu einem wesentlichen Bestandteil der Diabetestherapie. Diabetologe 2008; 4 (5): 361–367. EK IIICrossRef

65.

American Diabetes Association. 14. Diabetes Care in the Hospital. Diabetes Care 2017; 40 (Suppl. 1): S120–S127. https://doi.org/10.2337/dc17-S017. EK IVCrossRef

66.

Chen HS, Wu TE, Jap TS et al. Effects of health education on glycemic control during holiday time in patients with type 2 diabetes mellitus. Am J Manag Care 2008; 14 (1): 45–51. EK Ib/LoEPubMed

67.

Canadian Diabetes Association. 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Im Internet: http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf; Stand: 23. Juli 2017. EK IV

68.

Graveling AJ, Frier BM. Hypoglycaemia: an overview. Prim Care Diabetes 2009; 3 (3): 131–139. EK IIICrossRef

69.

Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57 (12): 3169–3176. EK III

70.

Deary IJ, Hepburn DA, MacLeod KM et al. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 1993; 36 (8): 771–777. EK III/LoE 3CrossRef

71.

McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001; 18 (9): 690–705. EK III

72.

Haak T, Kellerer M (2009) Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. Mainz: Kirchheim. Deutsche Diabetes Gesellschaft, EK IV

73.

Kitabchi AE, Umpierrez GE, Murphy MB et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29 (12): 2739–2748. EK IV

74.

Kitabchi AE, Umpierrez GE, Miles JM et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32 (7): 1335–1343. EK IV

75.

Bull SV, Douglas IS, Foster M et al. Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: results of a nonrandomized trial. Crit Care Med 2007; 35 (1): 41–46. EK IIb

76.

Joint British Diabetes Societies for inpatient care. The Management of Diabetic Ketoacidosis in Adults. Second Edition Update: September 2013. Im Internet: http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_DKA_Adults_Revised.pdf; Stand: 23. Sept. 2017. EK IV

77.

Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Typ-2-Diabetes – Nierenerkrankungen bei Diabetes im Erwachsenenalter. Version Konsultation 1.0; 2010. EK IV

78.

Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes – Langfassung, 2. Auflage. Version 2. Im Internet: http://www.netzhautkomplikationen.versorgungsleitlinien.de; Stand: 19. Okt. 2017. EK IV

79.

Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2010) Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter. Ek Iv

80.

Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Typ-2-Diabetes – Präventions- und Behandlungsstrategien für Fuβkomplikationen. Version 2.8; 2006. EK IV

81.

Bundesärztekammer, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Kassenärztliche Bundesvereinigung (2010) Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. Ek Iv

Titel: Therapie des Typ-1-Diabetes
Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057–013; 2. Auflage), Stand: 30. Juni 2018
verfasst von: Thomas Haak
Stefan Gölz
Andreas Fritsche
Martin Füchtenbusch
Thorsten Siegmund
Elisabeth Schnellbächer
Harald H. Klein
Til Uebel
Diana Droßel
Publikationsdatum: 22.02.2019
Verlag: Springer Medizin
Schlagwörter: Typ-1-Diabetes
Hypoglykämie
Insuline
Insuline
Ketoazidose
Erschienen in: Die Diabetologie / Ausgabe 2/2019
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-019-0458-8

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Daten aus den Praxen: Komorbiditäten bei Typ‑2-Diabetes

DDG Praxisempfehlungen: Definition, Klassifikation und Diagnostik des Diabetes mellitus

Diabetes im Blick – Nationale Diabetes-Surveillance

Verbesserung der glukosesenkenden Therapie bei Typ-2-Diabetes

Wirkung von Omega-3-Fettsäuren bei Diabetes mellitus

Auswirkungen von Hypoglykämien auf kardiovaskuläre Ereignisse

Praxisempfehlungen der Deutschen Diabetes Gesellschaft